Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
MKC-1
CASI Pharmaceuticals
Pancreatic Cancer
1 trial -
MKC-1
CASI Pharmaceuticals
Ovarian Cancer
1 trial -
MKC-1
CASI Pharmaceuticals
Breast Cancer
1 trial -
MKC-1
CASI Pharmaceuticals
Advanced Cancer
2 trials -
ML43332
Hoffmann-La Roche
Solid tumors
1 trial -
MLN0264
Takeda
Adenocarcinoma of the Stomach
1 trial -
MLN0264
Takeda
Pancreatic Adenocarcinoma
1 trial -
MOGAMULIZUMAB
Ningbo Cancer Hospital
Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))
1 trial -
MOR208C115
Incyte
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
MORAb-202-G000-201
Eisai Co.,
Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).
1 trial -
MRG003
Shanghai University of Traditional Chinese Medicine
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
1 trial -
MRG003 combined with Dalpicicilip
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial -
MRG003 combined with Pucotenlimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
MRTX1719
Bristol-Myers Squibb Australia Pty Ltd
Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
MRx0518
4D Molecular Therapeutics
Oncology
1 trial -
MRx0518
4D Molecular Therapeutics
Urothelial Carcinoma
1 trial -
MS200095-0031
Merck Sharp and Dohme
Lung Cancer
1 trial -
MS201924_0002
Merck Sharp and Dohme
Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy
1 trial -
MS201924_0022
Merck Sharp and Dohme
Non-Squamous Non-Small Cell Lung Cancer
1 trial -
MT-401
Marker Therapeutics
Acute Myeloid Leukemia
1 trial -
MaaT033 capsule
Regeneron UK Limited
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Mektovi film-coated tablets for metastatic colorectal cancer wi…
Disc Medicine
metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)
1 trial -
Metformin Hydrochloride ER
Atrium Therapeutics
Sarcoma Metastatic
1 trial -
Methotrexate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Central Nervous System Lymphoma
1 trial -
Methotrexate tablets
The First People's Hospital of Lianyungang
Solid Tumors
1 trial -
Midostaurin
Novartis Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
Mifamurtide
Takeda
Osteosarcoma
1 trial -
Mifepristone
CORCEPT THERAPEUTICS INC
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Mitomycin C
United Therapeutics Europe Ltd
Bladder Cancer
1 trial -
Mitomycin C
HALOZYME THERAPEUTICS, INC.
Bladder Cancer
1 trial -
Mitoxantrone Hydrochloride Liposome
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B-cell Lymphoma
1 trial -
Mitoxantrone liposome
The First People's Hospital of Lianyungang
Relapsed or Refractory Acute Myeloid Leukemia
1 trial -
MoLuoDan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Precancerous Condition
1 trial -
Modakafusp Alfa
Teva Generics B.V
Neoplasms
1 trial -
Modakafusp Alfa
Teva Pharma GmbH
Neoplasms
1 trial -
Monalizumab
MedImmune
Advanced Solid Tumors
1 trial -
Mosunetuzumab
Adaptive Biotechnologies Corp
Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
Mosunetuzumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Follicular Lymphoma
1 trial -
Motixafortide
Regeneron UK Limited
Pancreatic Cancer
1 trial -
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
Multi-epitope HER2 Peptide Vaccine TPIV100
United Therapeutics Europe Ltd
Breast Adenocarcinoma
1 trial -
Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Sana Biotechnology
Breast Cancer
1 trial -
NALIRIFOX+Adebrelimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
NAP (Naptumomab estafenatox)
BRIGHT MINDS BIOSCIENCES INC.
Non-small Cell Lung Cancer
1 trial -
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
RELMADA THERAPEUTICS, INC.
Non Muscle Invasive Bladder Cancer
1 trial -
NEO-201 in combination with pembrolizumab
Chongqing Precision Biotech Co., Ltd
Non Small Cell Lung Cancer
1 trial -
NEO-TIM
Fondazione Telethon ETS
high-risk, surgically resectable BRAF mutated and wild-type Melanoma
1 trial -
NERATINIB
PUMA BIOTECHNOLOGY, INC.
Stage IV (Metastatic) Breast Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.